{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T21:27:13Z","timestamp":1795210033073,"version":"4.10.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"UNC Thurston Arthritis Research Center Dean\u2019s Fund"},{"name":"TARC 2019 Pilot Research Grant"},{"DOI":"10.13039\/100006108","name":"NIH National Center for Advancing Translational Sciences","doi-asserted-by":"crossref","award":["#UL1TR002489"],"award-info":[{"award-number":["#UL1TR002489"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"crossref"}]},{"name":"UNC CCCR Grant","award":["NIH\/NIAMS P30AR072580"],"award-info":[{"award-number":["NIH\/NIAMS P30AR072580"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Immune checkpoint inhibitors (ICIs) enhance the immune system\u2019s ability to target and destroy cancer cells, but this non-specific immune overactivation can result in immune-related adverse events (irAEs). Patients with underlying autoimmune diseases were excluded from the original ICI clinical trials because of the theoretical risk of irAEs. This study aimed to evaluate the risk of irAEs in patients with pre-existing rheumatologic diseases on ICIs, impact of anti-rheumatic therapy on irAEs, and malignancy outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a retrospective chart review of patients with a pre-existing rheumatologic diagnosis receiving ICIs at the University of North Carolina from 2014 to 2019. Risk differences (RD) and asymptotic 95% confidence intervals (95% CIs) using a continuity correction along with odds ratios (OR) and exact 95% CIs were produced between pre-specified risk factors and flares of the underlying rheumatologic disease and\/or irAEs. Kaplan\u2013Meier survival estimates for time to unfavorable cancer response between subsets of patients were compared using the log-rank test.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified 45 patients receiving an ICI with an underlying rheumatologic diagnosis, including 22 with rheumatoid arthritis (RA). Overall, 13 patients (29%) had a flare of their autoimmune disease, 20 patients (44%) had a new-onset irAE, and 27 (60%) had either a flare or new-onset irAE. Patients with RA had higher risk of flares compared to those with other rheumatologic disorders (45% vs 13%, RD 32%, 95% CI 2.0\u201356.8); all RA flares were\u2009\u2264\u2009grade 2 and treated in the outpatient setting. Concurrent treatment of the rheumatologic disease at the start of ICI therapy was not associated with a reduced risk of flare (OR 0.86, 95% CI 0.19\u20133.76) or new onset irAE (OR 3.21, 95% CI 0.83\u201313.6) compared to those not on anti-rheumatic medications. Anti-rheumatic therapy did not impact time to unfavorable malignancy outcome (<jats:italic>p<\/jats:italic>\u2009=\u20090.52).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The majority of our study cohort experienced a flare or new onset irAE with ICI treatment. Treatment with anti-rheumatic therapy did not prevent disease flares or new onset irAEs, but did not negatively impact malignancy outcomes. Research is needed to determine safe anti-rheumatic therapy options to prevent flares and irAEs that do not interfere with malignancy outcomes.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s41927-022-00297-5","type":"journal-article","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:03:59Z","timestamp":1667865839000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy"],"prefix":"10.1186","volume":"6","author":[{"given":"Amanda","family":"Lusa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Saxena Beem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumey","family":"Ishizawar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,8]]},"reference":[{"issue":"7","key":"297_CR1","doi-asserted-by":"publisher","first-page":"vii7","DOI":"10.1093\/rheumatology\/kez418","volume":"58","author":"L Spiers","year":"2019","unstructured":"Spiers L, Coupe N, Payne M. Toxicities associated with checkpoint inhibitors-an overview. Rheumatology (Oxford). 2019;58(7):vii7\u201316.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"297_CR2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1208\/s12248-021-00574-0","volume":"23","author":"JD Twomey","year":"2021","unstructured":"Twomey JD, Zhang B. Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. AAPS J. 2021;23(2):39.","journal-title":"AAPS J"},{"issue":"3","key":"297_CR3","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","volume":"77","author":"M Kostine","year":"2018","unstructured":"Kostine M, Rouxel L, Barnetche T, Veillon R, Martin F, Dutriaux C, et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis. 2018;77(3):393\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"297_CR4","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1634\/theoncologist.2018-0823","volume":"24","author":"BM Warner","year":"2019","unstructured":"Warner BM, Baer AN, Lipson EJ, Allen C, Hinrichs C, Rajan A, et al. Sicca syndrome associated with immune checkpoint inhibitor therapy. Oncologist. 2019;24(9):1259\u201369.","journal-title":"Oncologist"},{"key":"297_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","volume":"106","author":"A Moreira","year":"2019","unstructured":"Moreira A, Loquai C, Pfohler C, Kahler KC, Knauss S, Heppt MV, et al. Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur J Cancer. 2019;106:12\u201323.","journal-title":"Eur J Cancer"},{"issue":"5","key":"297_CR6","doi-asserted-by":"publisher","first-page":"669","DOI":"10.3899\/jrheum.200367","volume":"48","author":"KB Almutairi","year":"2021","unstructured":"Almutairi KB, Nossent JC, Preen DB, Keen HI, Inderjeeth CA. The prevalence of rheumatoid arthritis: a systematic review of population-based studies. J Rheumatol. 2021;48(5):669\u201376.","journal-title":"J Rheumatol"},{"issue":"10","key":"297_CR7","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.autrev.2017.07.022","volume":"16","author":"E Giat","year":"2017","unstructured":"Giat E, Ehrenfeld M, Shoenfeld Y. Cancer and autoimmune diseases. Autoimmun Rev. 2017;16(10):1049\u201357.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"297_CR8","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","volume":"2","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2016;2(2):234\u201340.","journal-title":"JAMA Oncol"},{"issue":"19","key":"297_CR9","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","volume":"36","author":"GC Leonardi","year":"2018","unstructured":"Leonardi GC, Gainor JF, Altan M, Kravets S, Dahlberg SE, Gedmintas L, et al. Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders. J Clin Oncol. 2018;36(19):1905\u201312.","journal-title":"J Clin Oncol"},{"issue":"3","key":"297_CR10","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/art.40397","volume":"70","author":"MD Richter","year":"2018","unstructured":"Richter MD, Pinkston O, Kottschade LA, Finnes HD, Markovic SN, Thanarajasingam U. Brief report: cancer immunotherapy in patients with preexisting rheumatic disease: the mayo clinic experience. Arthritis Rheumatol. 2018;70(3):356\u201360.","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"297_CR11","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1002\/art.41068","volume":"71","author":"A Tison","year":"2019","unstructured":"Tison A, Quere G, Misery L, Funck-Brentano E, Danlos FX, Routier E, et al. Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide multicenter cohort study. Arthritis Rheumatol. 2019;71(12):2100\u201311.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"297_CR12","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1634\/theoncologist.2018-0618","volume":"24","author":"A Cortellini","year":"2019","unstructured":"Cortellini A, Buti S, Santini D, Perrone F, Giusti R, Tiseo M, et al. Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-programmed death-1 immunotherapy: a real-world transverse study. Oncologist. 2019;24(6):e327\u201337.","journal-title":"Oncologist"},{"key":"297_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","volume":"91","author":"FX Danlos","year":"2018","unstructured":"Danlos FX, Voisin AL, Dyevre V, Michot JM, Routier E, Taillade L, et al. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer. 2018;91:21\u20139.","journal-title":"Eur J Cancer"},{"issue":"2","key":"297_CR14","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/annonc\/mdw443","volume":"28","author":"AM Menzies","year":"2017","unstructured":"Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017;28(2):368\u201376.","journal-title":"Ann Oncol"},{"key":"297_CR15","doi-asserted-by":"publisher","first-page":"641","DOI":"10.7326\/M20-3419","volume":"171","author":"MK van der Kooij","year":"2021","unstructured":"van der Kooij MK, Suijkerbuijk KPM, Aarts MJB, van den Berkmortel F, Blank CU, Boers-Sonderen MJ, et al. Safety and efficacy of checkpoint inhibition in patients with melanoma and preexisting autoimmune disease: a cohort study. Ann Intern Med. 2021;171:641\u20138.","journal-title":"Ann Intern Med"},{"issue":"6","key":"297_CR16","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1093\/annonc\/mdw056","volume":"27","author":"B Lee","year":"2016","unstructured":"Lee B, Wong A, Kee D, Neeson P, Shackleton M, McArthur G, et al. The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma. Ann Oncol. 2016;27(6):1174\u20137.","journal-title":"Ann Oncol"},{"key":"297_CR17","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/RHU.0000000000001314","volume":"27","author":"E Efuni","year":"2020","unstructured":"Efuni E, Cytryn S, Boland P, Niewold TB, Pavlick A, Weber J, et al. Risk of toxicity after initiating immune checkpoint inhibitor treatment in patients with rheumatoid arthritis. J Clin Rheumatol. 2020;27:267\u201371.","journal-title":"J Clin Rheumatol"},{"key":"297_CR18","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jbi.2015.05.003","volume":"55","author":"DA Hanauer","year":"2015","unstructured":"Hanauer DA, Mei Q, Law J, Khanna R, Zheng K. Supporting information retrieval from electronic health records: a report of University of Michigan\u2019s nine-year experience in developing and using the electronic medical record search engine (EMERSE). J Biomed Inf. 2015;55:290\u2013300.","journal-title":"J Biomed Inf"},{"key":"297_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2017.09.002","volume":"119","author":"B El Osta","year":"2017","unstructured":"El Osta B, Hu F, Sadek R, Chintalapally R, Tang SC. Not all immune-checkpoint inhibitors are created equal: meta-analysis and systematic review of immune-related adverse events in cancer trials. Crit Rev Oncol Hematol. 2017;119:1\u201312.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"297_CR20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","volume":"11","author":"H Nishimura","year":"1999","unstructured":"Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11(2):141\u201351.","journal-title":"Immunity"},{"issue":"8","key":"297_CR21","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.autrev.2017.05.025","volume":"16","author":"S Sandigursky","year":"2017","unstructured":"Sandigursky S, Silverman GJ, Mor A. Targeting the programmed cell death-1 pathway in rheumatoid arthritis. Autoimmun Rev. 2017;16(8):767\u201373.","journal-title":"Autoimmun Rev"},{"issue":"7","key":"297_CR22","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1002\/art.27500","volume":"62","author":"AP Raptopoulou","year":"2010","unstructured":"Raptopoulou AP, Bertsias G, Makrygiannakis D, Verginis P, Kritikos I, Tzardi M, et al. The programmed death 1\/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis. Arthritis Rheum. 2010;62(7):1870\u201380.","journal-title":"Arthritis Rheum"},{"key":"297_CR23","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.2147\/CMAR.S188551","volume":"11","author":"J Li","year":"2019","unstructured":"Li J, He Q, Yu X, Khan K, Weng X, Guan M. Complete response associated with immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis of nine randomized controlled trials. Cancer Manag Res. 2019;11:1623\u20139.","journal-title":"Cancer Manag Res"},{"issue":"17","key":"297_CR24","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1200\/JCO.2017.75.6270","volume":"36","author":"C Robert","year":"2018","unstructured":"Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, et al. Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J Clin Oncol. 2018;36(17):1668\u201374.","journal-title":"J Clin Oncol"},{"issue":"3","key":"297_CR25","doi-asserted-by":"publisher","first-page":"546","DOI":"10.3390\/cancers12030546","volume":"12","author":"F Petrelli","year":"2020","unstructured":"Petrelli F, Signorelli D, Ghidini M, Ghidini A, Pizzutilo EG, Ruggieri L, et al. Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Cancers (Basel). 2020;12(3):546.","journal-title":"Cancers (Basel)"},{"issue":"22","key":"297_CR26","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1200\/JCO.19.00189","volume":"37","author":"B Ricciuti","year":"2019","unstructured":"Ricciuti B, Dahlberg SE, Adeni A, Sholl LM, Nishino M, Awad MM. Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications. J Clin Oncol. 2019;37(22):1927\u201334.","journal-title":"J Clin Oncol"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-022-00297-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-022-00297-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-022-00297-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T11:16:10Z","timestamp":1701342970000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcrheumatol.biomedcentral.com\/articles\/10.1186\/s41927-022-00297-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,8]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["297"],"URL":"https:\/\/doi.org\/10.1186\/s41927-022-00297-5","relation":{},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,8]]},"assertion":[{"value":"3 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by the Institutional Review Board of the University of North Carolina at Chapel Hill prior to start of data collection under IRB 17-1841. All methods were performed in accordance with the relevant guidelines and regulations<b>.<\/b> Due to the retrospective design and observational nature of the study, the requirement for informed consent was waived by the ethics committee of the University of North Carolina at Chapel Hill.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"64"}}